英夫利昔单抗治疗成功的坏疽性脓皮病继发于司库奇尤单抗：一例病例报告并文献复习。

Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review.

机构信息

Department of Dermatology, Otaru General Hospital, Otaru, Hokkaido, Japan.

Department of Dermatology, The Hokkaido Medical Center, Sapporo, Hokkaido, Japan.

出版信息

Clin Exp Dermatol. 2022 Jul;47(7):1372-1374. doi: 10.1111/ced.15183. Epub 2022 Apr 22.

DOI:10.1111/ced.15183

PMID:35298047

Abstract

We report a case of pyoderma gangrenosum (PG) caused by secukinumab, which was successfully treated with risankizumab. We also reviewed reported cases of PG caused by interleukin (IL)-17 inhibitors. The clinical course of this case indicates that IL-23 may play an important role in the pathogenesis of PG and therefore IL-23-targeting therapies may be a treatment option for PG.

摘要

我们报告了一例由司库奇尤单抗引起的坏疽性脓皮病（PG），该病例成功地接受了 risankizumab 治疗。我们还回顾了报告的由白细胞介素（IL）-17 抑制剂引起的 PG 病例。该病例的临床过程表明，IL-23 可能在 PG 的发病机制中发挥重要作用，因此，IL-23 靶向治疗可能是 PG 的一种治疗选择。